# US 2017/0246290 A1 · Oil-in-water emulsion influenza vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0246290 A1
- Document ID: US20170246290A1
- Status: Published application
- Kind: A1
- Application number: 15/446,508
- Filed: 2017-03-01
- Published: 2017-08-31
- Earliest claimed: 2007-04-20
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals SA
- Inventors: William Ripley BALLOU; Emmanuel Jules HANON
- Web page: https://patentgrep.com/patent/US20170246290A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16251: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg HA or a low amount such as less than 15 μg HA.

## Claims

### Claim at position 1

-60. (canceled)

### Claim 61

A method for the preparation of an immunogenic composition in a dose volume suitable for human use,
wherein the immunogenic composition comprises an aqueous suspension that comprises an influenza virus antigen or antigenic preparation prepared in the presence of less than or equal to 5 μg/ml thiomersal;
wherein the influenza virus antigen or antigenic preparation comprises 0.5 to 7 μg of haemagglutinin (HA) per dose per influenza strain;
wherein the immunogenic composition comprises an oil-in-water emulsion adjuvant that consists of an aqueous carrier, squalene and one or two emulsifying agents, and wherein the squalene is present in an amount from 0.5 mg to 9 mg and the one or two emulsifying agents are present in a total amount from 0.1 mg to 5 mg per human dose; the method comprising admixing a first volume of the oil-in-water emulsion adjuvant and a second volume of the aqueous suspension, wherein the first volume is greater than the second volume, and wherein the dose volume is between 0.25 ml and 1.5 ml.

### Claim 62 (depends on 61)

The method of claim 61, wherein the first volume is greater than the second volume.

### Claim 63 (depends on 61)

The method of claim 61, wherein the first volume is equal to the second volume.

### Claim 64 (depends on 61)

The method of claim 61, wherein the second volume is greater than the first volume.

### Claim 65 (depends on 61)

The method of claim 61, wherein the dose volume is between 0.5 ml and 1.5 ml.

### Claim 66 (depends on 61)

The method of claim 61, wherein the dose volume is 0.25 ml.

### Claim 67 (depends on 61)

The method of claim 61, wherein one or two of the one or two emulsifying agents is a non-ionic surfactant.

### Claim 68 (depends on 67)

The method of claim 67, wherein the one or two emulsifying agents is a polyoxyethylene sorbitan monooleate or a sorbitan trioleate or a mixture of both.

### Claim 69 (depends on 61)

The method of claim 61, wherein the one or two emulsifying agents are present at a total amount of 0.5-4 mg, per human dose.

### Claim 70 (depends on 61)

The method of claim 61, wherein the composition is a monovalent composition comprising a virus antigen or antigenic preparation from an influenza strain.

### Claim 71 (depends on 61)

The method of claim 61, wherein the composition is a multivalent composition comprising a virus antigen or antigenic preparation from at least two influenza strains.

### Claim 72 (depends on 61)

The method of claim 61, wherein the composition comprises a virus antigen or antigenic preparation from at least three interpandemic seasonal influenza strains.

### Claim 73 (depends on 61)

The method of claim 61, wherein the influenza strain is selected from the group consisting of: H2, H5, H9, H7, or H6.

### Claim 74 (depends on 61)

The method of claim 61, wherein the virus antigen or antigenic preparation comprises 1 to 5 μg HA per human dose per influenza strain per dose.

### Claim 75 (depends on 61)

The method of claim 61, wherein the virus antigen or antigenic preparation comprises 3.8 μg HA per influenza strain per dose.

### Claim 76 (depends on 61)

The method of claim 61, wherein the virus antigen or antigenic preparation comprises 1.9 μg HA per influenza strain per dose.

### Claim 77 (depends on 61)

The method of claim 61, wherein the virus antigen or antigenic preparation thereof is prepared from influenza virus grown in mammalian, avian or insect cells.

### Claim 78 (depends on 61)

The method of claim 61, wherein the virus antigen or antigenic preparation thereof is recombinantly produced.
